A PHASE 3, 26-WEEK, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF AC-1204 IN MILD-TO-MODERATE ALZHEIMER'S DISEASE: STUDY DESIGN AND PROGRESS